Src Family Kinase Inhibitors Antagonize the Toxicity of Multiple Serotypes of Botulinum Neurotoxin in Human Embryonic Stem Cell-Derived Motor Neurons

Neurotoxicity Research

Volumn 27, Issue 4, 2015, Pages 384-398

  Kiris, Erkan ^a,b,c   Burnett, James C ^c,d   Nuss, Jonathan E ^b   Wanner, Laura M ^b   Peyser, Brian D ^c   Du, Hao T ^c   Gomba, Glenn Y ^b   Kota, Krishna P ^b   Panchal, Rekha G ^b   Gussio, Rick ^c   Kane, Christopher D ^b,e,f   Tessarollo, Lino ^c   Bavari, Sina ^b  

^a Geneva Foundation   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Botulinum neurotoxins; Cell based assay; Drug discovery; Human embryonic stem cells; Motor neurons; Src inhibitors

Indexed keywords

BOTULINUM TOXIN; PROTEIN TYROSINE KINASE;

ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; EMBRYONIC STEM CELL; HUMAN; METABOLISM; MOTONEURON; PROTEIN DEGRADATION; SEROTYPE; SIGNAL TRANSDUCTION;

BOTULINUM TOXINS; EMBRYONIC STEM CELLS; HUMANS; MOTOR NEURONS; PROTEOLYSIS; SEROGROUP; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84939945588     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-015-9526-z     Document Type: Article

References (81)

1. Aleshin A, Finn RS (2010) SRC: a century of science brought to the clinic. Neoplasia 12(8):599–607
2. Apland JP, Biser JA, Adler M, Ferrer-Montiel AV, Montal M, Canaves JM, Filbert MG (1999) Peptides that mimic the carboxy-terminal domain of SNAP-25 block acetylcholine release at an Aplysia synapse. J Appl Toxicol 19(Suppl 1):S23–S26
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059–1070
4. Bajohrs M, Rickman C, Binz T, Davletov B (2004) A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep 5(11):1090–1095
5. Blanes-Mira C, Ibanez C, Fernandez-Ballester G, Planells-Cases R, Perez-Paya E, Ferrer-Montiel A (2001) Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue. Biochemistry 40(7):2234–2242
6. Bompiani KM, Dickerson TJ (2014) High-throughput screening technologies for botulinum neurotoxins. Curr Top Med Chem 14(18):2062–2080
7. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432(7019):925–929. doi:10.1038/nature03123
8. Brunger AT, Jin R, Breidenbach MA (2008) Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell Mol Life Sci 65(15):2296–2306. doi:10.1007/s00018-008-8088-0
9. Capek P, Zhang Y, Barlow DJ, Houseknecht KL, Smith GR, Dickerson TJ (2011) Enhancing the pharmacokinetic properties of botulinum neurotoxin serotype A protease inhibitors through rational design. ACS Chem Neurosci 2(6):288–293
10. Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV (2009) Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 8(11):3066–3074
11. Chen S (2012) Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins 4(10):913–939
12. Chen S, Barbieri JT (2011) Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem 286(17):15067–15072
13. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. doi:10.1158/0008-5472.CAN-09-1947
14. Coffield JA, Yan X (2009) Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther 330(1):352–358
15. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, Nergiz ME, Costanzo M, Baryshnikova A, Giaever G, Nislow C, Myers CL, Andrews BJ, Boone C, Roth FP (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7:544. doi:10.1038/msb.2011.71
16. Congleton J, MacDonald R, Yen A (2012) Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia 26(6):1180–1188. doi:10.1038/leu.2011.390
17. Deshpande SS, Sheridan RE, Adler M (1997) Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 35(3):433–445
18. Dolly JO, Lawrence GW, Meng J, Wang J, Ovsepian SV (2009) Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol 9(3):326–335
19. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312(5773):592–596. doi:10.1126/science.1123654
20. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19(12):5226–5237. doi:10.1091/mbc.E08-07-0765
21. Encinar JA, Fernandez A, Ferragut JA, Gonzalez-Ros JM, DasGupta BR, Montal M, Ferrer-Montiel A (1998) Structural stabilization of botulinum neurotoxins by tyrosine phosphorylation. FEBS Lett 429(1):78–82
22. Ferrer-Montiel AV, Canaves JM, DasGupta BR, Wilson MC, Montal M (1996) Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem 271(31):18322–18325
23. Fischer A (2013) Synchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons. Curr Top Microbiol Immunol 364:115–137. doi:10.1007/978-3-642-33570-9_6
24. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, Dickerson TJ, Johnson EA, Janda KD, Montal M (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 106(5):1330–1335. doi:10.1073/pnas.0812839106
25. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48(24):5631–5641. doi:10.1021/bi9002138
26. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2:e167. doi:10.1038/cddis.2011.50
27. Hakami RM, Ruthel G, Stahl AM, Bavari S (2010) Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol 18(4):164–172
28. Hebron ML, Lonskaya I, Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson’s disease models. Hum Mol Genet 22(16):3315–3328. doi:10.1093/hmg/ddt192
29. Hu BY, Zhang SC (2009) Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. Methods Mol Biol 636:123–137
30. Huang PP, Khan I, Suhail MS, Malkmus S, Yaksh TL (2011) Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS ONE 6(4):e19126
31. Ibanez C, Blanes-Mira C, Fernandez-Ballester G, Planells-Cases R, Ferrer-Montiel A (2004) Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett 578(1–2):121–127
32. Kao TJ, Palmesino E, Kania A (2009) SRC family kinases are required for limb trajectory selection by spinal motor axons. J Neurosci 29(17):5690–5700
33. Katsumata R, Ishigaki S, Katsuno M, Kawai K, Sone J, Huang Z, Adachi H, Tanaka F, Urano F, Sobue G (2012) c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS One 7(9):e46185
34. Keller JE, Cai F, Neale EA (2004) Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43(2):526–532
35. Kiris E, Nuss JE, Burnett JC, Kota KP, Koh DC, Wanner LM, Torres-Melendez E, Gussio R, Tessarollo L, Bavari S (2011) Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res 6(3):195–205. doi:10.1016/j.scr.2011.01.002
36. Kiris E, Burnett JC, Kane CD, Bavari S (2014a) Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem 14(18):2044–2061. doi:10.2174/1568026614666141022093350
37. Kiris E, Kota KP, Burnett JC, Soloveva V, Kane CD, Bavari S (2014b) Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn 14(2):153–168. doi:10.1586/14737159.2014.867808
38. Kostrzewa RM, Segura-Aguilar J (2007) Botulinum neurotoxin: evolution from poison, to research tool–onto medicinal therapeutic and future pharmaceutical panacea. Neurotox Res 12(4):275–290
39. Kota KP, Soloveva V, Wanner LM, Gomba G, Kiris E, Panchal RG, Kane CD, Bavari S (2014) A high content imaging assay for identification of botulinum neurotoxin inhibitors. J Vis Exp 93:e51915. doi:10.3791/51915
40. Larsen JC (2009) US army botulinum neurotoxin (BoNT) medical therapeutics research program: past accomplishments and future directions. Drug Dev Res 70:266–278
41. Lau CG, Takayasu Y, Rodenas-Ruano A, Paternain AV, Lerma J, Bennett MV, Zukin RS (2010) SNAP-25 is a target of protein kinase C phosphorylation critical to NMDA receptor trafficking. J Neurosci 30(1):242–254. doi:10.1523/JNEUROSCI.4933-08.2010
42. Lebeda FJ, Cer RZ, Mudunuri U, Stephens R, Singh BR, Adler M (2010) The zinc-dependent protease activity of the botulinum neurotoxins. Toxins 2(5):978–997. doi:10.3390/toxins2050978
43. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G, Socci ND, Tabar V, Studer L (2007) Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells 25(8):1931–1939
44. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659–666. doi:10.1038/nbt.1549
45. Li XJ, Hu BY, Jones SA, Zhang YS, Lavaute T, Du ZW, Zhang SC (2008) Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 26(4):886–893
46. Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL (2011a) Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorg Med Chem 19(24):7338–7348. doi:10.1016/j.bmc.2011.10.062
47. Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL (2011b) Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules 16(1):202–220. doi:10.3390/molecules16010202
48. Liu DZ, Cheng XY, Ander BP, Xu H, Davis RR, Gregg JP, Sharp FR (2008) Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. Neurobiol Dis 30(2):201–211
49. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, MacDonald JF (1999) G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 2(4):331–338. doi:10.1038/7243
50. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580(8):2011–2014
51. McNeish J, Roach M, Hambor J, Mather RJ, Weibley L, Lazzaro J, Gazard J, Schwarz J, Volkmann R, Machacek D, Stice S, Zawadzke L, O’Donnell C, Hurst R (2010) High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J Biol Chem 285(22):17209–17217
52. McNutt P, Celver J, Hamilton T, Mesngon M (2011) Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem Biophys Res Commun 405(1):85–90. doi:10.1016/j.bbrc.2010.12.132
53. Messa M, Congia S, Defranchi E, Valtorta F, Fassio A, Onofri F, Benfenati F (2010) Tyrosine phosphorylation of synapsin I by Src regulates synaptic-vesicle trafficking. J Cell Sci 123(Pt 13):2256–2265
54. Montecucco C, Molgo J (2005) Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5(3):274–279
55. Nuss JE, Wanner LM, Tressler LE, Bavari S (2010) The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity. J Biomol Screen 15(8):928–936. doi:10.1177/1087057110374996
56. Ohnishi H, Murata Y, Okazawa H, Matozaki T (2011) Src family kinases: modulators of neurotransmitter receptor function and behavior. Trends Neurosci 34(12):629–637. doi:10.1016/j.tins.2011.09.005
57. Opsenica IM, Tot M, Gomba L, Nuss JE, Sciotti RJ, Bavari S, Burnett JC, Solaja BA (2013) 4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity. J Med Chem 56(14):5860–5871. doi:10.1021/jm4006077
58. Patel K, Cai S, Singh BR (2014) Current strategies for designing antidotes against botulinum neurotoxins. Expert Opin Drug Discov 9(3):319–333. doi:10.1517/17460441.2014.884066
59. Pellett S (2013) Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol 364:257–285. doi:10.1007/978-3-642-33570-9_12
60. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA (2007) A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett 581(25):4803–4808
61. Peng L, Tepp WH, Johnson EA, Dong M (2011) Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog 7(3):e1002008. doi:10.1371/journal.ppat.1002008
62. Pless DD, Torres ER, Reinke EK, Bavari S (2001) High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 69(1):570–574
63. Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12(8):535–549. doi:10.1038/nrmicro3295
64. Salter MW, Kalia LV (2004) Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 5(4):317–328
65. Schenone S, Brullo C, Musumeci F, Biava M, Falchi F, Botta M (2011) Fyn kinase in brain diseases and cancer: the search for inhibitors. Curr Med Chem 18(19):2921–2942
66. Sen B, Johnson FM (2011) Regulation of SRC family kinases in human cancers. J Signal Transduct 2011:865819
67. Shu Y, Liu X, Yang Y, Takahashi M, Gillis KD (2008) Phosphorylation of SNAP-25 at Ser187 mediates enhancement of exocytosis by a phorbol ester in INS-1 cells. J Neurosci 28(1):21–30
68. Sikorra S, Henke T, Galli T, Binz T (2008) Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins. J Biol Chem 283(30):21145–21152. doi:10.1074/jbc.M800610200
69. Silhar P, Capkova K, Salzameda NT, Barbieri JT, Hixon MS, Janda KD (2010) Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc 132(9):2868–2869. doi:10.1021/ja910761y
70. Snyder DA, Kelly ML, Woodbury DJ (2006) SNARE complex regulation by phosphorylation. Cell Biochem Biophys 45(1):111–123. doi:10.1385/CBB:45:1:111
71. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S (2004) Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 10(9):1606–1611. doi:10.3201/eid1009.030745
72. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A (2014) Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett 588(7):1087–1093. doi:10.1016/j.febslet.2014.02.034
73. Sudhof TC (2013) Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 80(3):675–690. doi:10.1016/j.neuron.2013.10.022
74. Sun S, Tepp WH, Johnson EA, Chapman ER (2012) Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH. Biochemistry 51(28):5655–5662. doi:10.1021/bi3004928
75. Toth S, Brueggmann EE, Oyler GA, Smith LA, Hines HB, Ahmed SA (2012) Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol 3:102
76. Videnovic M, Opsenica DM, Burnett JC, Gomba L, Nuss JE, Selakovic Z, Konstantinovic J, Krstic M, Segan S, Zlatovic M, Sciotti RJ, Bavari S, Solaja BA (2014) Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria. J Med Chem 57(10):4134–4153. doi:10.1021/jm500033r
77. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci USA 102(28):9984–9989
78. Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S (2012) Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci 126(2):426–435. doi:10.1093/toxsci/kfr354
79. Wiesner A, Fuhrer C (2006) Regulation of nicotinic acetylcholine receptors by tyrosine kinases in the peripheral and central nervous system: same players, different roles. Cell Mol Life Sci 63(23):2818–2828. doi:10.1007/s00018-006-6081-z
80. 2+-sensitive exocytosis. J Gen Physiol 129(3):233–244. doi:10.1085/jgp.200609685
81. Zhang S, Yu D (2012) Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 33(3):122–128